BRIEF published on 11/18/2024 at 09:23, 3 days 4 hours ago Vivendi: Progress on the Split and Investor Events for Canal+ and Havas Investors Vivendi Canal+ Split Havas
PRESS RELEASE published on 11/18/2024 at 09:18, 3 days 4 hours ago Inside Information / Other news releases Vivendi updates on spin-off project for Canal+, Havas & Louis Hachette Group. Capital Markets Days planned with revenue & margin expectations for future growth Revenue Growth Financial Outlook Spin-off Vivendi Capital Markets Days
BRIEF published on 11/14/2024 at 08:41, 7 days 5 hours ago Vivendi to Redeem EUR 700 Million Notes Ahead of 2025 Maturity Shareholders' Meeting Redemption Vivendi Notes Make-whole Option
BRIEF published on 11/14/2024 at 08:40, 7 days 5 hours ago Vivendi Announces Full Redemption of EUR 700 Million Notes Shareholders' Meeting Vivendi Full Redemption EUR 700 Million Notes Make-whole Redemption
BRIEF published on 11/14/2024 at 08:40, 7 days 5 hours ago Vivendi Announces Full Redemption of EUR 500 Million Notes Shareholders’ Meeting Spin-off Redemption Vivendi Notes
PRESS RELEASE published on 11/14/2024 at 08:36, 7 days 5 hours ago Inside Information / Other news releases Vivendi SE announces full redemption of EUR 700,000,000 0.625% Notes due 11 June 2025. Redemption conditional on shareholder meeting. Paying Agent: Société Générale Securities Services Société Générale Redemption Shareholder Meeting Vivendi SE Paying Agent
PRESS RELEASE published on 11/14/2024 at 08:35, 7 days 5 hours ago Inside Information / Other news releases Vivendi SE issues full redemption notice for EUR 700,000,000 1.125% Notes due 11 December 2028, conditional on shareholders' meeting approval Shareholders' Meeting Financial Market Vivendi SE Redemption Notice Make-whole Redemption
PRESS RELEASE published on 11/14/2024 at 08:35, 7 days 5 hours ago Inside Information / Other news releases Vivendi SE announces full redemption of EUR 500,000,000 1.875% Notes due 26 May 2026 and conditions for Optional Redemption Date on 13 December 2024 Redemption Vivendi SE EUR 500,000,000 1.875% Notes Optional Redemption Date
BRIEF published on 11/08/2024 at 14:01, 12 days 23 hours ago Vivendi publishes a key document for its split project Vivendi Canal+ Split Louis Hachette Havas
PRESS RELEASE published on 11/08/2024 at 13:56, 12 days 23 hours ago Terms of availability of the preparatory documents for the GM Vivendi publishes information document for spin-off project involving Canal+, Havas, and Louis Hachette Group, to be voted on December 9, 2024, creating independent entities listed on different stock exchanges Financial Advisors Shareholders' Meeting Spin-off Vivendi Information Document
Published on 11/21/2024 at 13:30, 11 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 11 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 41 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 41 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 41 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 6 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 26 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 43 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 21 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 56 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 56 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
